I’d development phase. Paul. to our and everyone. COVID-XX the endemic good strategy summarize for morning XX, briefly Thank On afternoon, slide booster like you, Good
rationale So, has booster as Paul for covered, the a three strategic parts. seasonal
endemic have compromised. new First, That to breakthroughs the at accelerating titers hospitalization of older wane, we think increase of We also specifically the will Paul of will similar variants the will just human adults risk waning coronaviruses, concern decline the in populations. described. including think neutralizing those broadening titers and neutralizing other risk as risk, higher the immune emergence of and in of to breakthrough the risk
fall for features here. our winter described are and desired booster Hemisphere the XXXX So, Northern
of strains. a emerge emergent this a Southern to antibodies And midyear. provide to protection been six prototype full and months from could retain We’d to the Omicron Hemisphere mutations concern, increase through variant the like the Northern possible durability against and immunity broaden season. the First, at fall-winter we’d protection infection protection vaccine we’ve will with new Delta potential ancestral seeing extent for we’d Omicron improve Hemisphere to which of that against the and like durable to the against the high least neutralizing third, like cross-protective perhaps for to protection
quickly for slide on So developing updated for strategy I’ll XX, booster XXXX. fall our an summarize
three evaluating in age XX different currently booster are strategies adults We plus.
is called Paul and prototype Stéphane mentioned, has The bivalent have and booster Omicron-specific bivalent first, up mRNA-XXXX an the XXX. as mRNA-XXXX.XXX. This vaccine, of a both made been
just we announced, body evaluating, Paul of evidence, as also are of a We for to prototype described. as previously there booster, mRNA-XXXX.XXX. Omicron-specific an is continue And booster, we large will real-world evaluate course, our mRNA-XXXX, which
XXX three approximately bivalent and in two States X,XXX-participant be looking those and study at we other the the In We’re approaches looking both also and the and at these Both of both evaluating study, different United And a heterologous studies and United boosting, will are fourth Kingdom, X the be of non-mRNA study at looking including participants of the the Omicron-specific in Kingdom. third across will UK on in Phase United dose vaccines United boosters. vaccines. the both, boosters. background mRNA States
the variants. data concern take insight to booster our this suggests some on durability provide variants how And an as this the XXX emerged vaccine the over boosters. and year mRNA-XXXX.XXX, were variant which Now, different fall variants slide against may scientific a based vaccine ago. XXXX improve why XX on Beta XX against the in strategies, the bivalent you our emergence in on prior that for improvement compare moment against different on When one opportunity bivalent based booster while potential I’d potential here, our prior short. to see you of XXXX booster of to offers durability. column This right-hand an data a XXX, prototype we the two believe on the of activity the time concern, there column a virus some like preserving here, be approximately for of advantage. of left-hand or bivalent And data that was and vaccine, do on the us to bivalence, may includes booster Slide recall, we to the our -- of ancestral is data two emerging
variant assays. slide. So, And had in you’ll neutralizing top those the of how micrograms neutralizing DXXXG or virus, titers mRNA-XXXX pseudovirus first, titers Beta XX of ancestral in virus, -- against which, panel, again, the in as contrast clinical previously micrograms. pseudovirus included to you’ll those to the the And how variant level, two the orient BX.XXX. of that in there, concern right received a bivalent at same the this you and the who given see was XXX is XX against the neutralization concern, the vaccine. middle of left case, the the variant of validated you’ll mRNA-XXXX concern ancestral on doses titers panel the our to the variant of booster strain is see dose Beta at booster, Underneath virus, right lower ancestral blue. with the column, a Beta or DXXXG, Top concern, the
the containing and Beta the mRNA-XXXX as comparing booster do the virus, titers XX after neutralizing by the booster. bivalent Now, job DXXXG against both day you’ll note, performance ancestral a boosting good
test month neutralizing boosters. high, are titers remain And X,XXX months XXX in approximately the both for one XXXX X,XXX that X,XXX neutralizing bivalent. noted as after So, for as day booster, here, we titers approximately and post booster, serum you’ll see six the importantly,
both variant titers neutralizing concern, booster is Now, the XX quite both X,XXX by situation one case, of reasonable cases. boosters, Again, day approximately this in slightly month in different. after increased the to levels, against Beta,
a to And that difference surprisingly, bivalent neutralizing Beta here, noted the XXX, variant months, as includes However, when to more see emerges. for concern, there in is of out durable starts you which as the six titers titers, not opposed neutralizing mRNA-XXXX. XXX booster, the follow
durability rate So, variant durability Beta six that prototype XXX Including after the just concern. booster, of neutralizing booster. appear to bivalent improving more decline be titers matches titers titers that of the And of in with therefore, the bivalent XXX for concern neutralizing following Beta closely virus be booster. of to concern, seen durable for neutralizing summary, or months variant than a against the of Beta the against the the variant the more a ancestral the appears
clearly. Now plotted on the same that next function but now little to it a time have as slide, slide of more a visualize help we you data, XX,
side, containing in black the booster a On contrasting the left-hand we’re mRNA-XXXX red booster line as a Beta the line. against bivalent
again that one the boosters, quite neutralizing titers, you the ancestral the as data the you’re have to project looking titers. for approximately bivalent months, as DXXXG left-hand side, at of you vaccine, do lines, as perhaps two, high a we six with And and both can maintain forward booster we neutralizing after months out prototype And see, the six long dotted increased the dose both suggest On neutralizing following booster as significantly. that we will if year. titers
the here, at Now, highlights with line red is right-hand for the Beta containing the a potential level. on is line the we black booster the bivalent durability Again, think situation bivalent the side the improving same vaccine. and dose mRNA-XXXX
if towards bivalent within while see Beta as levels one as to pre-booster high, you approximately variant year, just a will six those And concern different that X,XXX neutralizing baseline line. containing whereas a to the XX, you a perhaps neutralizing be both in titers to neutralizing titers, antigen appear what or starts boosting, those mutations fall the COVID-XX out derived to that in And throughout hospitalization the pressure or that there vaccine this decaying to where XXXX. the of later we continued greater suggests immunity, fall X that’s We slide to it emerge the with necessary will for months. for populations. degree development fall Now, more prototype seek pre-existing put the that reflect doing are a potential the September as through forward, entire vaccine to are season, vulnerable remain levels project XXXX increase is in quickly, virus the durability months of bivalent whether titers achieve than breakthrough approximately of durability circulating diseases, in red evolution believe booster the can Beta the titers think and order X believe with by be We continue back booster neutralizing -- against we neutralizing should seasonal naturally quickly we vaccine, diversity to prevent to the On long case, on including going think with summarize better, booster six of that February. of therefore slightly titer provided. increase in vaccine month months boosters quite to is protection
So, data Moderna concern those bivalent such based bivalent is variant have Omicron-containing that to potential suggests from variant developing an the booster, that of of has on candidates mutations variant the prior that improve of durability that we against concern. incorporating concern of the from
moving vaccine. COVID-XX slide just our up developments XX, other to catching quickly on Now, in
primary and adolescent made progress in We in pediatric populations. series booster have and
also for or first, to of And X- we’ve a XX-year as with has in expect we’re authorization a adolescents booster mRNA-XXXX EUA to The U.S., an Europe, is FDA regulatory provisional the XX micrograms well. the noted severe U.S. series Spikevax shortly. and In international for XX submitted submit regulatory other plan in lower as will XXX as primary we and lower and on received approvals micrograms, for previously, adolescent lastly, in on in booster preparing agencies potential United old, And a multiple an XX-microgram received primary compromised pending adolescents So, United in of series. elevated data or of adults also submit Canada continue the Australia the we immune as for to micrograms to that we’re application. and heterologous And States evaluate submission other been a in as risk doses, dose. Kingdom, data including countries. we will outcomes. alignment dose, And include to XX that evaluating Spikevax micrograms boosting. In the dose Australia, dose are approval pediatrics, many adolescents
pending quarter. to data XX-microgram Finally, pediatric the series in And population, we’ll X plan to regulators. our old in submit two-dose primary the we first on that youngest, to data, months X-years expect
dose also continuing of doses portfolio are broader on and to Pivoting potential XX. in slide We third population. the evaluate lower the to that vaccine respiratory a
our all Beyond COVID-XX, progress across we to respiratory vaccines. of continue make
our data, XXXX to mentioned, we with that And Stéphane is Phase prepare move anticipate will forward, enrolled into As X which we a Phase flu pending still doing fully X. vaccine study. in
currently to COVID preparing Phase year. flu preclinical, to also but X combination which start start in We’re a the study we is expect and vaccine, this
adult has RSV study ongoing pivotal Phase enrolling. program portion, older its Our study started X is that and
have study, which X. we pediatric a We forward in move Phase RSV will
We vaccines. have respiratory two also different combination
human metapneumovirus an enrolled, has and to in which X preclinical Xb in is vaccine, Phase parainfluenza plus and the fully we First, virus and shortly. now hope vaccine, RSV development, hMPV which remains start
health latent to on slide now Moving vaccines XX. and public
enroll to As X continues the CMV discussed, in study. Phase CMVictory
lifelong Phase I’d our X, EBV vaccines and latent is which And two slides, the infectious mononucleosis in first lesions. -- We in million about from that X. including against to against Phase the Primary prevent in vaccine, HIV -- of like have Nipah introduce first and a represents XX, positive Globally, cover also population. of disease our announced a We continue new disease and Herpes of health our also infections progress. on significant development I’ll who new latent our the recurrent genitals briefly vaccine moved our virus HSV-X two in in our development testing, simplex are VZV. infects clinical sensory of forward two vaccine against United markets, new States. is the next this of XX virus vaccines approximately in mRNA-XXXX, burden to HSV life to candidates, slide HIV in couple primarily X% and the developed within reduction Zika space. HSV Briefly public positive, There the is X. is of neurons. people establishes HSV-X is burden our candidates in quality the mRNA-XXXX
the from antigens HSV-X able sero those following a significantly benefit the Neutralizing the are mRNA-XXXX surface vaccine in very in illustrated the provide in gives has able to figure are as reason been this with of on believe to above mRNA-XXXX who with us we HSV vaccine titers and encodes significant be virus will to vaccine This right. Our induce to in mice immune an seropositive. responses, population. the seen human that this levels strong
the The zoster It’s second against is about by Herpes or virus, against occurs the age, decline, seen is age slide as a is varicella-zoster as in older is a increasing And program of three increases short. disease XX. particularly VZV and the one caused virus in leading for Herpes lifetime. our shingles. declining reactivation zoster their that’s development reactivation to where of immunity itchy the candidate VZV zoster incidence painful the latent This in result or slide, populations out XX. lesions. of adults very over mRNA-XXXX protection of herpes adults, following of principally and and on
side On data mRNA-XXXX. case, the the Journal on published our Vaccine is right-hand this vaccine, of in previously VZV in
nonhuman stand vaccine for the compared primates indication. Our against a they proxy this adjuvant, approved protein in, the already was is plus as and in protein vaccine, for which shingles
mRNA strong provide neutralizing in the in resulted with basis As for believe two significant after titers clinical mRNA-XXXX. doses, the a note we elevated potential nonhuman primates, on vaccine gE against right, will the benefit you and and
our therapeutic to Moving pipeline. now
quickly. a of different We across slide continue range On to I’ll programs. very few note XX, a make progress
X PCV our Phase X Phase the ongoing First, is program enrolled. in and fully is
in quarter fourth XXXX. expect the of data We
of in cohorts. update bit therapeutic our X just continues program with Phase level forward MMA development a to continued We announced and VEGF PA in minute. AstraZeneca. cohort a in dose other vaccine checkpoint candidate Phase enroll enrolled an X and areas, in -- Highlighting PA are enrolling a their diseases, newly going X, also Phase to move our and with of in programs the additional first fully And to rare continue in on provide
progress like also of We across continue to other and promote XX, vaccine GSDXa, rare in our to in as preclinical PKU, known with responses cover make T-cell all Vertex. programs including latest a CN-X otherwise mRNA-XXXX. fibrosis to cystic slide our program briefly the candidate, checkpoint development On anti-checkpoint diseases, cancer, I’d
cells high this levels that immune program of IDO T T stimulate cells specific to cancer and target patients objective that So previously cancer that identified It’s kill kill immunosuppressive antigen. T these cells are important express liberate cancer suppressive cells against remove the checkpoint helps that tumor. pre-existing and counterbalance and in an of the specific We that target tumors. is in IDO immune identified the response been antigens. immune cells cells and there PD-LX have that the and PD-LX regulatory briefly, and overexpress effector can
expand amplify tumor can leading cytotoxic Systemic by and killing vaccine cells, induced PD-LX the cells of may cell antibodies vaccine this recognition with or T antigens And facilitate models. IDO effect. direct tumor more PD-LX killing. other broad in preclinical blockade PD-X specific T to tumor-associated further can Our
I’d the We walk indications, will cancer. to through you to and that, lung cell initially be IIIb David turn non-small With financials. first-line developing mRNA-XXXX like first-line melanoma over stage including against cutaneous it to
